CA Patent

CA2939952C — Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery

Assigned to University of Pittsburgh · Expires 2022-03-22 · 4y expired

What this patent protects

A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is sustainably released for a period of at least…

USPTO Abstract

A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is sustainably released for a period of at least five days.

Drugs covered by this patent

Patent Metadata

Patent number
CA2939952C
Jurisdiction
CA
Classification
—
Expires
2022-03-22
Drug substance claim
No
Drug product claim
No
Assignee
University of Pittsburgh
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.